Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Jan;20(1):88.
doi: 10.1634/theoncologist.2014-0284.

In reply

Binghe Xu  1 , Andrew Seidman  2 , Stephen Chan  3
Affiliations
Comment

In reply

Binghe Xu et al. Oncologist. 2015 Jan.

Abstract

Many factors contribute to patient survival in metastatic breast cancer and other late-stage cancers. It is doubtful that adjuvant therapy causes a worse survival outcome. This being said, should resistance develop following adjuvant therapy, the patient needs to be offered a first-line solution that is free of cross-resistance.

PubMed Disclaimer

Comment in

Comment on

References

    1. Fink MK, Kleeberg UR, Bartels S, et al. Adjuvant therapy-related shortening of survival (ATRESS): An underrated phenomenon [letter] The Oncologist. 2015;20:88. - PMC - PubMed
    1. Seidman AD, Chan S, Wang J, et al. A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist. 2014;19:443–452. - PMC - PubMed
    1. Pierga J-Y, Asselain B, Jouve M, et al. Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer. 2001;91:1079–1089. - PubMed
    1. Palmieri C, Jones A. The 2011 EBCTCG polychemotherapy overview. Lancet. 2012;379:390–392. - PubMed
    1. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405–410. - PubMed